Pay in 4 interest-free payments of $5.68 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
LY3502970 (ZEUS): an oral small-molecule (non-peptide) GLP-1 receptor agonist by Lilly, which has such a long half-life that it was considered for weekly or monthly dosing
We take reports regarding patient safety seriously and actively monitor, evaluate, and report safety information for all our medicines
Background Obesity is a chronic metabolic disease that increases the risk of several other diseases, including type 2 diabetes, cardiovascular disease, chronic kidney disease, liver disease, and certain cancer types
Mullins, R., & Chandalia, M
Eli Lilly has now announced positive topline results from two additional Phase 3 trials of retatrutide, adding to what is now a growing body of late-stage clinical evidence
US$ 27.85
US$ 22.10
US$ 22.17
US$ 20.10
US$ 28.26
